Guselkumab biosimilar (CTTQ Pharma)

古塞奇尤单抗生物类似药（正大天晴）

Report date: 2026/05/14 20:00:28
First In Class

Base Information

Drug NameGuselkumab biosimilar (CTTQ Pharma)
Drug Alias NameGuselkumabum古塞奇尤单抗注射液Tremphia谷瑟库单抗古塞库人单抗 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesN/A
Active IndicationsPlaque psoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG